Details for Patent: 10,137,167

Which drugs does patent 10,137,167 protect, and when does it expire?

Patent 10,137,167 protects NOCDURNA and is included in one NDA.

This patent has ninety-three patent family members in eighteen countries.

Summary for Patent: 10,137,167

Title:	Methods comprising desmopressin
Abstract:	The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Inventor(s):	Klein; Bjarke Mirner (Frederiksberg, DK), Norgaard; Jens Peter (Frederiksberg, DK)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	14/143,866
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,137,167

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-002	Jun 21, 2018		DISCN	Yes	No						TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

International Family Members for US Patent 10,137,167

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2724653
Canada	2793502
China	102821776
China	106924716